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Background: Bladder transitional cell carcinoma greatly threatens human health all over the world. Tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) shows a strong apoptosis-inducing effect on a variety of cancer
cells including bladder cancer. However, adenovirus-mediated TRAIL expression still showed cytotoxicity to normal
cells mainly due to lack of tumor specificity.
Methods: To solve the problem, we applied miRNA response elements (MREs) of miR-1, miR-133 and miR-218 to
confer TRAIL expression with specificity to bladder cancer cells.
Results: Expression of miR-1, miR-133 and miR-218 was greatly decreased in bladder cancer than normal bladder
tissue. Luciferase assay showed that application of the 3 MREs was able to restrain exogenous gene expression to
within bladder cancer cells. Subsequently, we constructed a recombinant adenovirus with TRAIL expression
regulated by MREs of miR-1, miR-133 and miR-218, namely Ad-TRAIL-MRE-1-133-218. qPCR, immunoblotting and
ELISA assays demonstrated that Ad-TRAIL-MRE-1-133-218 expressed in bladder cancer cells, rather than normal
bladder cells. The differential TRAIL expression also led to selective apoptosis-inducing and growth-inhibiting effect
of Ad-TRAIL-MRE-1-133-218 on bladder cancers. Finally, bladder cancer xenograft in mouse models further
confirmed that Ad-TRAIL-MRE-1-133-218 effectively suppressed the growth of bladder cancers.
Conclusions: Collectively, we demonstrated that MREs-based TRAIL delivery into bladder cancer cells was feasible
and efficient for cancer gene therapy.
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Among the most common malignant cancers, bladder
transitional cell carcinoma severely risks health of the
people on the earth [1]. Downregulation of certain tumor
suppressor genes was documented to largely contribute to
initiation, progression, invasion and metastasis of bladder
cancer [2]. Therefore, gene therapy is a reasonable strategy
for bladder cancer treatment and many reports have
confirmed its feasibility and effectiveness [3,4].* Correspondence: zhaoyg717@163.com
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reproduction in any medium, provided the orTumor necrosis factor-related apoptosis-inducing lig-
and (TRAIL) has attracted much attention due to its
specific induction of apoptosis in various types of cancer
cells by binding death receptors and activating
mitochondria-independent signal transduction pathway
[5,6]. Like many other cancer types, adenovirus-mediated
TRAIL therapy was well demonstrated to inhibit the
survival of bladder cancer cells [7-12]. More intriguingly,
extensive DR4 and DR5 expressions of bladder cancer in
patients ensure its responsiveness to TRAIL in future
clinical treatment [13].
Cytotoxicity to normal cells, however, seriously
hurdles the clinical application of adenoviral vector for
cancer gene therapy, since adenoviral vector lacks the
ability to discriminate cancer and normal cells. To confertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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developed many strategies including employing cancer-
specific promoter. Although UP II promoter has been used
to specifically drive TRAIL expression in bladder cancer
cells, more novel strategies are needed to prevent the cyto-
toxicity of adenovirus-based gene therapy to normal
cells [14-16].
Differential expression profile of miRNAs has been
widely reported between bladder cancer and normal cells
[17]. Decreased expression level of certain miRNAs
allows the introduced genes specifically expressed in
bladder cancer cells by inserting their miRNA response
elements (MREs) following the opening reading frames.
So far, no groups have tested the feasibility and effective-
ness of this MREs-based strategy for bladder cancer-
specific gene therapy.
Here, we intended to identify suitable MREs for blad-
der cancer specific adenovirus-mediated TRAIL expres-
sion from the miRNAs with downregulated expression
in bladder cancer, including miR-1 [18-21], miR-99a [22],
miR-100 [23], miR-101 [24,25], miR-125b [23,26,27], miR-
133a [18,20,21,23,28-30], miR-143 [22,23,31-33], miR-145
[21,23,29-31,34], miR-195-5p [35], miR-199a-3p [36],
miR-200 [37,38], miR-203 [39,40], miR-205 [37], miR-218
[21,41], miR-490-5p [42], miR-493 [43], miR-517a [44],
miR-574-3p [45], miR-1826 [46] and let-7c [42].
Methods
Primary culture
We employed primary cultures derived from bladder
transitional carcinoma and normal bladder mucosal cells
(BMC) in this study. For the culturing of bladder cancer,
the samples were obtained with written informed con-
sent from all patients according to protocols approved
by Ethical Review Board in General Hospital of Chengdu
Military Area Command of Chinese PLA (Chengdu,
China). All patients underwent surgical resection of
bladder carcinoma at Department of Urology, General
Hospital of Chengdu Military Area Command of Chinese
PLA (Chengdu, China). Bladder cancer samples were
sheared into small pieces, followed by mechanical ma-
nipulation to obtain single cell suspension. The primary
cultures were maintained in DMEM supplemented with
15% FBS.
For primary BMC culture, the samples were obtained
from 8 patients that underwent cystoscopic examination
of asymptomatic haematuria (The biopsies were not ma-
lignant revealed by histopathological results). The previ-
ously described procedures that have been approved by
Ethical Review Board in General Hospital of Chengdu
Military Area Command of Chinese PLA (Chengdu,
China) was followed to establish the primary BMC culture
[47]. The BMCs were immortalized using adenoviral
vector, Adeno-SV40 (Applied Biological Materials Inc.,Canada), according to the manufacturer’s instructions. All
the patients approved the application of their samples for
this study.
Construction of adenoviral vectors
Ad-EGFP and Ad-TRAIL were preserved in our laboratory.
We constructed Ad-TRAIL-MRE-1-133-218 as follows. A




GCACAA-3′), which contained two copies of miR-1
MREs, two copies of miR-133 MREs and two copies of
miR-218 MREs. This fragment was released from the
temporary vector by EcoRV and then inserted into
pShuttle-CMV-TRAIL at the same site, generating
pShuttle-CMV-TRAIL-MRE-1-133-218. This plasmid
was subsequently cotransfected into HEK-293 cells with
pAdEasy. After plague purification for three times and
PCR-based identification, adenoviruses were harvested
and then purified with the CsCl gradient centrifugation.
The involved adenoviruses were titrated with TCID50
method on HEK-293 cells and represented as plaque-
forming units per milliliter (pfu/ml) [48]. The adeno-
virus was designated as Ad5-TRAIL-MRE-1-133-218.
The structures of these adenoviruses were shown in
Figure 1a.
Cell line cultures
Human bladder transitional cell carcinoma cell line T24
and RT-4 were both purchased from the American Type
Culture Collection (Manassas, VA) and were grown in
McCoy’s 5a Medium Modified (Life Technologies,
Rockville, MD) supplemented with 10% (v/v) fetal bovine
serum (Life Technologies, Rockville, MD). Human endo-
thelial cells HUV-EC-C and normal liver cells L-02 were
obtained from Shanghai Cell Collection (Shanghai,
China). HUV-EC-C and L-02 cells were cultured using
DMEM media supplemented with 10% (v/v) fetal bovine
serum. All media was supplemented with 4 mM glutam-
ine, 100 units/mL penicillin and 100 μg/ml strepto-
mycin. All cells in this experiment were cultured under
a 5% CO2 and humidified atmosphere at 37°C.
Quantitative PCR (qPCR)
Total RNA was extracted from 14 bladder cancer samples
with Trizol solution (Sigma-Aldrich, MO) and pooled as
one group for subsequent experiments. Another pool of
RNA was also obtained from 8 normal bladder mucosal
tissues according to the same protocol. Also, T24, RT-4,
HUV-EC-C and L-02 cells were processed for extracting
RNA with Trizol solution. Reverse transcription reaction
was subsequently performed with TaqManW MicroRNA













































































Figure 1 MREs of miR-1, miR-133 and miR-218 enabled adenovirus-mediated adenoviral vector to express TRAIL with bladder cancer
specificity. (a) Illustration was shown of the structures of the involved adenoviral vectors. Ad-TRAIL-MRE-1-133-218 contained MREs of miR-1, miR-133
and miR-218 that were inserted immediately following TRAIL gene. ITR: inverse terminal region. (b) qPCR assay was performed to detect TRAIL mRNA
expression. TRAIL mRNA levels in Ad-TRAIL cells were selected as standards and GAPDH was selected as endogenous reference. Means ± SEM of three
independent experiments were shown. (c) TRAIL protein level was also determined in T24 and RT-4 bladder cells as well as BMCs infected with
different adenoviruses by immunoblotting. GAPDH was selected as endogenous reference. (d) TRAIL protein level was also evaluated in the same cells
infected with the indicated adenoviruses by ELISA assay. Means ± SEM of three independent experiments were shown. (e) T24 cells were treated with
both 10 MOI of Ad-TRAIL-MRE-1-133-218 and mixed mimics of miR-1, miR-133 and miR-218 (100 nM for each) or control mimics (300 nM). 48 h later,
TRAIL expression was tested by immunoblotting assay. GAPDH was selected as endogenous reference.
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formed with TaqManW 2 × Universal PCR Master Mix
(Applied Biosystems) on CFX96™ Real-Time PCR Detec-
tion System (Bio-Rad Laboratories, CA) supplied with ana-
lytical software.
4 × 104 cells were cultured in each well of 6-well
plates. TRAIL mRNA abundance was determined in
Ad-TRAIL-MRE-1-133-218-infected cells after treated
with 10 MOI of adenoviruses. After 48h, cells were lysed
for RNA extraction and then inversely transcribed into
cDNAs with Rever Tra Ace qPCR RT Kit (Toyobo,
Japan) according to the manufacturer’s instructions.
qPCR was performed with SYBR premix Ex Taq
(TaKaRa) on CFX96™ Real-Time PCR Detection System(Bio-Rad Laboratories, CA) supplied with analytical
software.
Immunoblotting assay
Protein in adenovirus-infected cells was quantified with
immunoblotting assay. 3.5 × 105 cells were cultured in
each well of 6-well plates. 10 MOI of adenoviruses were
added to cell cultures. Proteins were lyzed with M-PERW
Mammalian Protein Extraction Reagent (Thermo Scientific,
IL) after 48 h, separated using polyacrylamide gel elec-
trophoresis and transferred onto 0.45 μm nitrocellulose
membranes. 5% fat-free dry milk was used for blocking.
The membrane was then incubated with specific pri-
mary antibodies for 6h. The membrane was incubated











































The underscored sequences indicated MREs of miR-1, miR-99a, miR-101,
miR-133 and miR-218, miR-490-5p, miR-493 and miR-517a.
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SuperSignal West Dura Extended Duration Substrate
(Thermo Scientific, IL).
TRAIL determination by ELISA assay
We performed ELISA assay to evaluate the secreted TRAIL
protein in media. Briefly, 3.5 × 105 cells were cultured in
each well of 6-well plates. 10 MOI of adenoviruses were
added to cell media. After 48h, two-antibody sandwich
ELISA was applied to determine human TRAIL expression
level in the supernatant of cells. The involved antibodies are
monoclonal mouse anti-human TRAIL antibody (R&D
Systems), peroxidase-conjugated rabbit anti-goat IgG
(H&L) and goat anti-human TRAIL antibody (R&D
Systems). The absorbance was assessed at a 450 nm
wavelength.
miRNA mimics treatment
miR-1, miR-133, miR-218 and control mimics were
synthesized by GenePharma (Shanghai, China). T24 and
RT-4 cells were transfected with 300 nM control mimic
or the mixture of 100 nM miR-1, 100 nM miR-133 and
100 nM miR-218.
FACS analysis on apoptotic rates
3.5 × 105 cells were cultured in each well of 6-well plates.
After 24h, the cells were infected with adenoviruses of 10
MOI. After 48h, the cells were stained with Annexin V-PE
Apoptosis Detection Kit (Biovision, CA) based on the
manufacturer’s instructions. The percentages of apoptotic
cells were examined with FACS analysis.
Luciferase assay
The synthesized DNA constructs, which contains two
copies of indicated MREs, were inserted into the XhoI
and NotI sites of psiCheck2 vectors (Promega, WI) to
construct recombinant luciferase reporter (psiCheck2-*).
The involved MREs sequences in our study were
described in detail in Table 1.
4 × 104 cells were cultured in each well of 24-well
plates. After transfecting T24, RT-4 and BMCs with the
above plasmids, cells were processed with lysis buffer,
and subsequently, luciferase activities were assessed with
the Dual-Luciferase reporter system (Promega, WI)
according to the manufacturers’ instructions.
Cell viability assay
1 × 104 T24 and RT-4 cells, 1.5 × 104 primary bladder can-
cer cells or 2 × 104 BMCs were cultured in each well of 96-
well plates. Adenoviruses of indicated MOIs were added to
cell cultures. After 6d, 50 μl of MTT (1 mg/ml) was added,
and 4 h later, MTT-containing media was replaced with
150 μl of DMSO. The spectrophotometric absorbance was
assessed on a model 550 microplate reader (Bio-RadLaboratories, Hercules, CA) at 570 nm with a reference
wavelength of 655 nm. Cell viability = absorbance value of
infected cells / absorbance value of uninfected control cells.
Animal experiments
Procedures for animal experiments were all approved by
the Committee on the Use and Care on Animals in
Qingdao Municipal Hospital (Qingdao, China).
2×106 T24 cells were inoculated at the left flanks of 5-
week-old female BALB/c nude mice (Institute of Animal
Center, Chinese Academy of Sciences, Shanghai, China).
When tumors reached 7–9 mm in diameter, 24 mice were
equally assigned into 4 groups (n=6). 100 μL of PBS with
or without 2×108 pfu of Ad-EGFP, Ad-TRAIL and Ad-
TRAIL-MRE-1-133-218 was directly administrated into
tumors by injection, respectively. The administrations were
performed every other day for five times with a total dosage
of 1×109 pfu of adenoviruses.
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1.5×106 cells at the right flanks of 5-week-old female
BALB/c nude mice. 24 mice were equally divided into 4
groups (n=6). The doses of used adenoviruses and injec-
tion procedures were the same as those on T24 tumor
xenograft.
We periodically measured tumor diameter using
calipers. Tumor volume (mm3) = maximal length (mm) ×
perpendicular width (mm) 2 / 2.
Liver function evaluation
To evaluate the hepatoxicity induced by adenovirus
treatment, BALB/c mice (n=5) were intravenously
injected with 1×109 pfu of indicated adenoviruses every
other day for five times. On day 11, their blood (600
mL/mice) was harvested by cardiac puncture, followed
by being incubated with 12 U of heparin. Alanine
aminotransferase (ALT) levels in blood were detected at
the Clinical Laboratory, Qingdao Manucipal Hospital
(Qingdao, China).
Histological staining
On day 7 after adenovirus injection, one mouse was
sacrificed from each group and its tumor, brain and liver
were collected and fixed according to the routine
procedures. Histological staining was then performed on
formalin-fixed, paraffin-embedded tumor, brain and liver
tissue sections using the streptavidinbiotin peroxidase
complex method. Anti-TRAIL antibody (Santa Cruz Bio-
technology, CA) was used to specifically recognize
TRAIL protein. The sections were finally counterstained
with hematoxylin.
Statistical analysis
The statistical tests in this manuscript were two-tailed
student’s t-test. Differences were considered as statistically
significant (*) when P < 0.05 and statistically very signifi-
cant (**) when P < 0.01.
Results
The expression levels of 8 miRNAs were greatly reduced
in bladder cancer cells
To experimentally identify downregulated miRNAs in can-
cerous tissues derived from bladder epithelium, we studied
miRNA expression profiles in 14 bladder cancer samples.
qPCR assay showed that expression levels of all the tested
miRNAs were decreased in bladder cancer cells in com-
parison with 8 noncancerous bladder tissue. Among them,
miR-1, miR-99a, miR-101, miR-133a, miR-218, miR-490-
5p, miR-493 and miR-517a had reduction of greater than
90% in their expression level (P<0.01) (Figure 2a). Also, we
detected the expression levels of miR-1, miR-99a, miR-101,
miR-133a, miR-218, miR-490-5p, miR-493 and miR-517a
in T24 and RT-4 bladder cancer cell lines. Consistently,their levels were reduced in the tested cell lines (Additional
file 1: Figure S1). The differential expression profile of
miRNAs ensured the possibility of utilizing these miRNAs
to specifically express genes of interests in bladder cancer
cells.
Application of MREs of miR-1, miR-133 and miR-218
restrained exogenous gene expression within bladder
cancer cells.
To assess if MREs of miR-1, miR-99a, miR-101, miR-133a,
miR-218, miR-490-5p, miR-493 and miR-517a could be
used for bladder cancer-specific delivery of exogenous
genes, we constructed a series of reporter plasmids
containing luciferase regulated by their MREs. The data
revealed that luciferase expression was only slightly
affected in bladder cancer cells transfected with the re-
porter plasmids that were regulated by MREs of miR-1,
miR-101, miR-133a, miR-218 and miR-490-5p (Figure 2b).
Furthermore, inhibitory effect on luciferase expression was
greater than 80% in bladder mucosal cells (BMCs) when
MREs of miR-1, miR-133a and miR-218 were used
(P<0.01) (Figure 2b). Furthermore, HUV-EC-C and normal
liver cells L-02 have been shown to have much higher ex-
pression level of miR-1, miR-133a and miR-218 than blad-
der cancer samples (Additional file 2: Figure S2).
Bladder cancer-specific expression of TRAIL genes was
achieved by employing MREs of miR-1, miR-133 and
miR-218
To confirm if combined application of MREs of miR-1, miR-
133 and miR-218 conferred TRAIL expression with bladder
cancer specificity, we simultaneously inserted the 3 MREs
immediately following TRAIL-encoding open reading frame
on adenoviral vectors (Figure 1a). qPCR assay showed that
the modified adenovirus, Ad-TRAIL-MRE-1-133-218, had a
similar level of TRAIL gene to that of Ad-TRAIL in bladder
cancer while TRAIL expression was greatly suppressed in
Ad-TRAIL-MRE-1-133-218-infected BMC (Figure 1b).
Immunoblotting and ELISA assays also confirmed that
Ad-TRAIL-MRE-1-133-218 infection resulted in TRAIL
expression with a comparative level with Ad-TRAIL, but
almost no TRAIL expression was detected in normal
bladder mucosal cells infected with Ad-TRAIL-MRE-1-
133-218 (Figure 1c and d).
To confirm MRE-regulated TRAIL expression was de-
pendant on the level of corresponding miRNAs, Ad-
TRAIL-MRE-1-133-218-infected T24 cells were treated
with mixed mimics of miR-1, miR-133 and miR-218.
Elevated expression level of these miRNAs led to a great
reduction in TRAIL expression in bladder cancer cells
(Figure 1e).
The above results verified that simultaneous application
of MREs of miR-1, miR-133 and miR-218 conferred


































































































































































































































Figure 2 MREs-regulated expression of exogenous gene in bladder cancer cells. (a) Expression of different miRNAs was detected in the
pooled 14 bladder cancer and 8 normal bladder mucosal tissues. miRNA level in noncancerous bladder tissue was regarded as standard and U6
was selected as endogenous reference. Means ± SEM of three independent experiments were shown. (b) LuciferBMCase activity was quantified
in T24 and RT-4 bladder cells as well as s that were transfected with luciferase reporter plasmids. The luciferase activity in these cells transfected
with psiCheck2 was used as standard. Means ± SEM of three independent experiments were shown.
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specifically activated extrinsic apoptotic pathway in
bladder cancer cells
As a well-known proapoptotic protein, TRAIL induced
apoptosis in a variety of cancer types through activating
extrinsic apoptotic pathway. Therefore, we investigated
if normal bladder mucosal cells evaded the apoptosis
induced by TRAIL expression by Ad-TRAIL-MRE-1-
133-218. FACS analysis showed that apoptosis took
place selectively in bladder cancer cells, rather than nor-
mal bladder cells, when Ad-TRAIL-MRE-1-133-218 was
employed. In contrast, Ad-TRAIL induced apoptosis
both in bladder cancerous and normal cells. In addition,there was no significant difference in apoptotic rate
between Ad-TRAIL- and Ad-TRAIL-MRE-1-133-218-
treated bladder cancer cells, suggesting no impairment
of apoptosis-inducing capacity caused by this modification
(Figure 3a).
We subsequently examined the activation of extrinsic
apoptosis pathway in T24, RT-4 and BMC cells by
immunoblotting assay. The data showed that caspase-8 was
cleaved in Ad-TRAIL and Ad-TRAIL-MRE-1-133-218-
infected bladder cancer cells as well as Ad-TRAIL-infected
BMCs. However, this cleavage did not take place in
Ad5-TRAIL-MRE-1-133-218-treated normal bladder mu-
cosal cells (Figure 3b). Similarly, cleavages of caspase-3
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patterns as caspase-8, suggesting extrinsic apoptotic path-
way was selectively activated in bladder cancer cells
when Ad5-TRAIL-MRE-1-133-218 was used (Figure 3b).Ad-TRAIL-MRE-1-133-218 decreased the survival of bladder
cancer cells rather than normal bladder mucosal cells
We next investigated the viability of bladder cancer cells and
BMCs with MTT assay, when Ad-EGFP, Ad-TRAIL and
Ad-TRAIL-MRE-1-133-218 were added to the indicated cell
cultures. The data revealed that Ad-TRAIL-MRE-1-133-218
had a comparative tumor-suppressing capacity on T24 and
RT-4 bladder cancer cells as well as primary bladder carcin-
oma cells with Ad-TRAIL (Figure 3c). However, Ad-TRAIL
had cytotoxicity to both cancerous and normal bladder
cells. In contrast, administration of Ad-TRAIL-MRE-1-


































































Figure 3 Anti-tumor capacity of Ad-TRAIL-MRE-1-133-218 on bladder
(a) Apoptosis was detected in the indicated cells by FACS analysis on Annexin
shown. (b) Cleavages of caspase 3, caspase 8 and PARP were determined by
proteins. GAPDH was selected as endogenous reference. (c) Viability of differe
The absorptive values of cells without adenovirus infection were used as stanCollectively, we proved that Ad-TRAIL-MRE-1-133-
218 inhibited the viability of bladder cancer cells without
significant cytotoxicity to normal cells.Ad-TRAIL-MRE-1-133-218 suppressed the growth of
bladder cancer xenograft in mouse models
Next, we intended to further investigate the suppressive
action of Ad-TRAIL-MRE-1-133-218 on bladder cancer
xenograft using mouse models. T24 and RT-4 bladder
cancer cells were used to establish the tumor xenografts.
We periodically recorded the growth of these bladder
cancer xenografts when Ad-EGFP, Ad-TRAIL and Ad-
TRAIL-MRE-1-133-218 were administered. The data
demonstrated that Ad-TRAIL and Ad-TRAIL-MRE-1-133-
218 had a similar growth-inhibiting effect on both T24 and
RT-4 bladder cancers (Figure 4a and b). The animal
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Figure 4 (See legend on next page.)
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Figure 4 Ad-TRAIL-MRE-1-133-218 suppressed the growth of bladder xenograft in mouse models. (a) T24 bladder cancer xenograft was
established by subcutaneously injecting 2×106 cells into left flanks of female BALB/c nude mice. 1×109 pfu of different adenoviruses were treated
and the tumor volumes were periodically measured. Means ± SEM of tumor sizes were shown. The arrows indicated time-points of adenovirus
injection. (b) RT-4 xenograft was established by subcutaneously injecting 1.5×106 cell into right flanks of female BALB/c nude mice. 1×109 pfu of
different adenoviruses were treated and the tumor volumes were periodically measured. Means ± SEM of tumor sizes were shown. The arrows
indicated time-points of adenovirus injection. (c) BALB/c nude mice (n=5) were intravenously injected with 1×109 pfu of different adenoviruses
every other days for five times. On day 11, their blood was harvested for the measurement of ALT levels. Means ± SEM of ALT serum levels were
shown. (d) Histological staining was performed to detect TRAIL expression in tumor and liver section from the tumor-bearing mice after
treatment of Ad-EGFP, Ad-TRAIL and Ad-TRAIL-MRE-1-133-218. The representative images were shown (×200).
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strong tumor-suppressing effect on bladder cancer.
To test the side effect induced by these adenoviruses, we
injected Ad-EGFP, Ad-TRAIL and Ad-TRAIL-MRE-1-133-
218 into BALB/c mice. On day 11, their blood was
collected and assayed for ALT level in serum. Ad-TRAIL
treatment was found to cause an elevated level of serum
ALT in mice. In contrast, Ad-TRAIL-MRE-1-133-218 did
not significantly change the ALT level in the blood of mice,
showing no cytotoxicity to liver cells (Figure 4c).
Also, TRAIL expression was evaluated in the tumor and
liver sections from the T24 tumor-bearing mice that
received the injection of Ad-EGFP, Ad-TRAIL and Ad-
TRAIL-MRE-1-133-218. The histological staining showed
that Ad-TRAIL-MRE-1-133-218 treatment resulted in
high expression of TRAIL in tumors as Ad-TRAIL infec-
tion (Figure 4d). Importantly, TRAIL expression was not
detected in liver section from Ad-TRAIL-MRE-1-133-
218-treated group, whereas Ad-TRAIL-infected mice had
an extensive TRAIL expression in their livers (Figure 4d).
Discussion
In this study, we experimentally confirmed expression
profiles of 20 miRNAs in bladder cancer and
corresponding noncancerous bladder tissues. qPCR assay
showed that all of them had lower abundance in bladder
cancer in comparison with normal bladder tissue. Our
results were in accordance with previous reports from
other research groups. The differential expression level
of these miRNAs made it feasible that their MREs can
be utilized to control TRAIL expression specifically in
bladder cancer cells.
Luciferase reporter assays showed that miR-1, miR-99a,
miR-101, miR-133a, miR-218, miR-490-5p, miR-493 and
miR-517a only had limited suppressive effect on luciferase
expression in bladder cancer cells when their MREs were
applied. Further investigation indicated that MREs of miR-
1, miR-133a and miR-218 inhibited luciferase expression in
normal bladder cells. Therefore, MREs of miR-1, miR-133a
and miR-218 were believed to prevent exogenous gene ex-
pression from normal bladder mucosal cells without
affecting its expression in bladder cancer cells.
UPII promoter has been utilized for specific TRAIL
expression in bladder cancer cells. However, geneexpression controlled by this promoter is not strictly
bladder cancer-specific, due to the remaining activity of
UPII promoter in normal bladder mucosal cells [49].
Therefore, other strategies should be developed for
preventing TRAIL expression from normal bladder cells.
We employed multidisciplinary approaches to prove that
TRAIL expression was greatly inhibited in Ad-TRAIL
-MRE-1-133-218-infected normal bladder epithelial cells.
These data demonstrated this recombinant adenovirus
as a vehicle for TRAIL expression with a high bladder
cancer-specificity.
As expected, Ad-TRAIL-MRE-1-133-218 induced extrin-
sic pathway-mediated apoptosis in bladder cancer cells, ra-
ther than normal bladder mucosal cells. Subsequent cell
viability assay and animal experiments showed that Ad-
TRAIL-MRE-1-133-218 greatly suppressed the growth of
bladder cancer. More importantly, survival of normal blad-
der epithelial cells was almost not affected by Ad-TRAIL
-MRE-1-133-218, suggesting biosafety of this MREs-
regulated TRAIL-expressing adenoviral vector.
To further improve the biosafety of the adenoviral
vector expressing TRAIL, other MREs should also be
applied to suppress the undesirable exogenous gene
expression in normal tissue, such as liver. miR-122 has
been extensively reported to be highly expressed in nor-
mal hepatic cells and downregulated in hepatocellular
carcinoma, and thus, its MRE can be utilized to prevent
cytotoxicity from liver cells [50].
TRAIL has been demonstrated as a potent anti-tumor
cytokine in our study. Other therapeutic cytokines also act
as candidates for cancer gene therapy, especially the natural
inhibitors against signaling pathway that is critical for cancer
progression. For example, DKK1 has been shown to sup-
press the gastric cancer progression by inhibiting WNT/β-
catenin pathway [51]. Our novel MRE-regulated adenoviral
vector is believed to be a suitable expression vehicle for
these inhibitors with high bladder cancer specificity.
Conclusions
We generated a bladder cancer-specific adenoviral vec-
tor that expressed TRAIL based on MREs of miRNAs
whose levels were reduced in bladder cancer. The anti-
tumor capacity and biosafety of this new adenoviral vec-
tor was proved by a series of experimental approaches.
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promising tool for gene therapy against bladder cancer.
Additional files
Additional file 1: Figure S1. Etoptic miRNA expression profile of T24
and RT-4 cells. Expression of miR-1, miR-99a, miR-101, miR-133a, miR-218,
miR-490-5p, miR-493 and miR-517a were detected in T24 and RT-4 cells.
miRNA level in noncancerous bladder tissue was regarded as standard
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